Celldex Therapeutics Inc. (CLDX)

2.30
0.05 2.22
NASDAQ : Health Technology
Prev Close 2.25
Open 2.25
Day Low/High 2.25 / 2.35
52 Wk Low/High 2.01 / 11.62
Volume 194.92K
Avg Volume 205.30K
Exchange NASDAQ
Shares Outstanding 15.02M
Market Cap 32.89M
EPS -14.50
P/E Ratio N/A
Div & Yield N.A. (N.A)
5 Dumbest Things on Wall Street

5 Dumbest Things on Wall Street

Blackberry's Flying Circus, Foolish Filmmaker, Celldex Shenanigans, Benmosche's Big Mouth and Chrysler's Conundrum highlight Gregg Greenberg's list of dumb things on Wall Street this week.

Biotech Stock Mailbag: Celldex, Exelixis, Geron, NPS Pharma

Biotech Stock Mailbag: Celldex, Exelixis, Geron, NPS Pharma

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

Biotech Breakouts

Biotech Breakouts

Favorable charts for Celldex, Repligen and Arrowhead Research.

Biotech Sell Side Tosses Billion-Dollar Valuation Bumps Like Mardi Gras Beads

Biotech Sell Side Tosses Billion-Dollar Valuation Bumps Like Mardi Gras Beads

Celldex and Isis Pharma received warm embraces from analysts Monday.

'Mad Money' Lightning Round: Take-Two Interactive Can Go Higher

'Mad Money' Lightning Round: Take-Two Interactive Can Go Higher

Cramer isn't selling Celldex Therapeutics but he's only buying ExOne for speculation.

Jim Cramer's 'Mad Money' Recap: Feeling Good About the Fed

Jim Cramer's 'Mad Money' Recap: Feeling Good About the Fed

While others criticize, Cramer praised the Federal Reserve for not cutting back at a time when the government could shut down.

Interesting CLDX Put And Call For October 19th

Interesting CLDX Put And Call For October 19th

Investors in Celldex Therapeutics, Inc. saw new options become available this week, for the October 19th expiration.

Celldex Therapeutics Inc. (CLDX): Today's Featured Health Care Winner

Celldex Therapeutics Inc. (CLDX): Today's Featured Health Care Winner

Celldex Therapeutics was a winner within the health care sector, rising $1.41 (7.4%) to $20.36 on average volume

5 Stocks Ready to Break Out

5 Stocks Ready to Break Out

These stocks look poised to break out and trade higher from current levels.

'Mad Money' Lightning Round: I'm Sticking With Pier 1

'Mad Money' Lightning Round: I'm Sticking With Pier 1

Cramer likes DexCom, thinks Himax Technologies is a buy but wants you to avoid SunPower.

Cramer's 'Mad Money' Recap: The Market's on a Roll

Cramer's 'Mad Money' Recap: The Market's on a Roll

Cramer is bowled over by all the good news pushing stocks higher.

Cramer's 'Mad Money' Recap: Things Are Going Too Well

Cramer's 'Mad Money' Recap: Things Are Going Too Well

Not only are certain sectors hot, but so is the U.S. economy, Cramer said, and that means an interest rate hike is not far away.

S&P 500 Hits Another High

While financial and energy sector strength boosted the broad index, the Nasdaq 100 is stuck in reversal mode, following Friday's selloff.

Off the Charts

Off the Charts

Maintain a long-side bias until composure changes.

Off the Charts

Off the Charts

The S&P is in an uptrend but the market is in digestion mode.

Celldex Therapeutics Inc. (CLDX): Today's Featured Drugs Laggard

Celldex Therapeutics Inc. (CLDX): Today's Featured Drugs Laggard

Celldex Therapeutics was a leading decliner within the drugs industry, falling $0.40 (-2.0%) to $19.55 on average volume

Celldex Therapeutics Announces Issuance Of Seminal Patent For CD27 Agonists

Celldex Therapeutics Announces Issuance Of Seminal Patent For CD27 Agonists

Patent Provides Broad-Based Intellectual Property Platform for CDX-1127

Celldex Stock Falls On Unusually High Volume (CLDX)

Celldex Stock Falls On Unusually High Volume (CLDX)

Celldex Therapeutics (Nasdaq:CLDX) is trading at unusually high volume Monday with 3.3 million shares changing hands. It is currently at two times its average daily volume and trading down 83 cents (-3.9%).

Celldex Might Be The Next Alexion? Buy Buy Buy!!

Celldex Might Be The Next Alexion? Buy Buy Buy!!

Speculation over Celldex's ultra-orphan drug candidate is the reason for the huge stock move.

Insider Trading Alert - Abercrombie & Fitch Company And 4 Others Traded By Insiders

Insider Trading Alert - Abercrombie & Fitch Company And 4 Others Traded By Insiders

Stocks with insider trader activity include ANF, MM, XCO, RNR and CLDX

'Mad Money' Lightning Round: Buy, Buy, Buy Five Below

'Mad Money' Lightning Round: Buy, Buy, Buy Five Below

Cramer thinks Six Flags is terrific and Kodiak Oil & Gas is a fine speculative stock.

Cramer's 'Mad Money' Recap: Ignore the Headlines

Cramer's 'Mad Money' Recap: Ignore the Headlines

The stock market is doing better than investors think, Cramer asserts.

'Mad Money' Lightning Round: Don't Sell MasterCard

'Mad Money' Lightning Round: Don't Sell MasterCard

Cramer is standing by Celldex Therapeutics but thinks Toll Brothers is in the penalty box.

Cramer's 'Mad Money' Recap: Time to Change Your Strategy

Cramer's 'Mad Money' Recap: Time to Change Your Strategy

Now that the Fed has spoken, Cramer said what will work best from here on out will be those companies that do better as the economy does better.

Feels Like a Bear Market

The best thing to do is get out of the way and let it play out.

The Action Has Shifted

And the close put an exclamation point on it.

TheStreet Quant Rating: D- (Sell)